SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
21.73
-0.11 (-0.50%)
At close: 4:00PM EDT

21.73 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close21.84
Open21.83
Bid13.38 x 900
Ask22.50 x 800
Day's Range21.47 - 22.14
52 Week Range16.26 - 23.95
Volume56,745
Avg. Volume45,112
Market Cap380.605M
Beta (3Y Monthly)0.22
PE Ratio (TTM)53.00
EPS (TTM)0.41
Earnings DateJul 14, 2017 - Jul 17, 2017
Forward Dividend & Yield0.24 (1.14%)
Ex-Dividend Date2019-04-23
1y Target Est21.50
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of SLP earnings conference call or presentation 9-Apr-19 8:15pm GMT

    Q2 2019 Simulations Plus Inc Earnings Call

  • Business Wire14 days ago

    Simulations Plus Releases ADMET Predictor® Version 9.5

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9.5 of its flagship machine learning modeling platform, ADMET Predictor®.

  • Simulations Plus Inc (SLP) Q2 2019 Earnings Call Transcript
    Motley Fool16 days ago

    Simulations Plus Inc (SLP) Q2 2019 Earnings Call Transcript

    SLP earnings call for the period ending February 28, 2019.

  • Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
    Zacks16 days ago

    Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates

    Simulations Plus (SLP) delivered earnings and revenue surprises of 20.00% and 4.59%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Simulations Plus: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Lancaster, California-based company said it had net income of 12 cents. The maker of software used in pharmaceutical research posted revenue of $8.5 million in the period. Simulations ...

  • Business Wire16 days ago

    Simulations Plus Reports Record Second Quarter FY2019 Revenue

    Quarterly Revenues Up 15%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share

  • The Simulations Plus (NASDAQ:SLP) Share Price Has Gained 230%, So Why Not Pay It Some Attention?
    Simply Wall St.21 days ago

    The Simulations Plus (NASDAQ:SLP) Share Price Has Gained 230%, So Why Not Pay It Some Attention?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put i...

  • Business Wire23 days ago

    Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call

    Simulations Plus, Inc. (SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2019 fiscal year, the period ended February 28, 2019, on Tuesday, April 9, 2019. The Company will host a conference call on April 9, 2019, at 4:15 p.m. Eastern Time. Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions.

  • Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for
    Zacks24 days ago

    Analysts Estimate Simulations Plus (SLP) to Report a Decline in Earnings: What to Look Out for

    Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Has Simulations Plus, Inc. (NASDAQ:SLP) Improved Earnings Growth In Recent Times?
    Simply Wall St.2 months ago

    Has Simulations Plus, Inc. (NASDAQ:SLP) Improved Earnings Growth In Recent Times?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! When Simulations Plus, Inc. (NASDAQ:SLP) released its most recent earningsRead More...

  • Top 4 Oil and Gas Penny Stocks for 2019
    Investopedia2 months ago

    Top 4 Oil and Gas Penny Stocks for 2019

    The oil and gas industry includes companies involved in the exploration, extraction, refining, transporting and marketing of oil and gas products. The oil and gas sector started 2018 off strong, coinciding with a rise in crude oil prices from around $50 to $70 per barrel.

  • Moving Average Crossover Alert: Simulations Plus
    Zacks3 months ago

    Moving Average Crossover Alert: Simulations Plus

    Simulations Plus, Inc. (SLP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Something To Consider Before Buying Simulations Plus, Inc. (NASDAQ:SLP) For The 1.2% Dividend
    Simply Wall St.3 months ago

    Something To Consider Before Buying Simulations Plus, Inc. (NASDAQ:SLP) For The 1.2% Dividend

    A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Historically, Simulations Plus, Inc. (NASDAQ:SLP) has paid Read More...

  • Business Wire3 months ago

    DILIsym Awarded $1.5 Million Phase II NIH Grant

    DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’ continued development, validation, and testing of its RENAsym software for predicting drug-induced kidney injury.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SLP earnings conference call or presentation 9-Jan-19 9:15pm GMT

    Q1 2019 Simulations Plus Inc Earnings Call

  • Business Wire3 months ago

    Simulations Plus Releases DDDPlus™ Version 6

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™. John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions.

  • Business Wire3 months ago

    DILIsym Services Inc. Initiates Development of IPFsym™

    DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems pharmacology) modeling software that will provide the ability to predict the efficacy of drugs being developed to treat idiopathic pulmonary fibrosis (IPF). The development of IPFsym is being sponsored by a large pharmaceutical company partner for $2.7 million, and it will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.

  • Business Wire3 months ago

    Simulations Plus to Present at the 21st Annual Needham Growth Conference

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m. ET (5:40 a.m. PT). In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.

  • Simulations Plus Inc (SLP) Q1 2019 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Simulations Plus Inc (SLP) Q1 2019 Earnings Conference Call Transcript

    SLP earnings call for the period ending November 30, 2018.

  • Simulations Plus (SLP) Q1 Earnings Lag Estimates
    Zacks3 months ago

    Simulations Plus (SLP) Q1 Earnings Lag Estimates

    Simulations Plus (SLP) delivered earnings and revenue surprises of -18.18% and 1.15%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Simulations Plus: Fiscal 1Q Earnings Snapshot

    The Lancaster, California-based company said it had profit of 9 cents per share. The maker of software used in pharmaceutical research posted revenue of $7.5 million in the period. Simulations Plus shares ...

  • Business Wire3 months ago

    Simulations Plus Reports First Quarter FY2019 Financial Results

    First quarter net revenues of $7.5 million reflecting 6.6% year over year growth

  • Should You Be Worried About Insider Transactions At Simulations Plus, Inc. (NASDAQ:SLP)?
    Simply Wall St.3 months ago

    Should You Be Worried About Insider Transactions At Simulations Plus, Inc. (NASDAQ:SLP)?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • Business Wire4 months ago

    DILIsym Services Inc. Releases DILIsym® Version 8A

    DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released DILIsym® Version 8A, its flagship QST (quantitative systems toxicology) modeling software. Dr. Paul Watkins, chair of the DILI-sim Scientific Advisory Board, said: “The DILI-sim Initiative input has led to this release of an updated version of the DILIsym tool. DILIsym version 8A includes many new important example compounds and addresses, for the first time, drug-induced injury to bile duct cells.

  • Business Wire4 months ago

    Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results

    Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST